TFF Pharmaceuticals
TFFP

$2.31

1.32%

Market Cap: $8.01M

About: TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.

Employees: 19

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

11% more funds holding

Funds holding: 19 [Q1] → 21 (+2) [Q2]

6.83% more ownership

Funds ownership: 13.96% [Q1] → 20.79% (+6.83%) [Q2]

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

50% less capital invested

Capital invested by funds: $2.13M [Q1] → $1.07M (-$1.06M) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for TFFP.

See Analyst Rankings

Financial journalist opinion

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID

Partnership funded by BARDA and other US government agencies TFF formulation may provide flexibility of delivery and improve storage and distribution conditions FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announces its new partnership with Emory University and the Biomedical Advanced Research and Development Authority (BARDA).

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

Zacks Investment Research

TFF Pharmaceuticals, Inc. (TFFP) Reports Q2 Loss, Tops Revenue Estimates

TFF Pharmaceuticals, Inc. (TFFP) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.70. This compares to loss of $3.50 per share a year ago.

TFF Pharmaceuticals, Inc. (TFFP) Reports Q2 Loss, Tops Revenue Estimates

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and achieved >80% of the previous oral trough blood levels -- leading to diminished drug burden 9 out of 9 (100%) patients who completed the 12-week treatment chose to remain on TFF TAC by proceeding to the long-term extension Phase; 2 patients have been treated for over a year and 6 patients have been treated for more than 6 months Observed a 6.5-fold reduction in the number of abnormally expressed rejection-related gene sets after treatment with TFF TAC No production of donor-specific antibodies (DSA) after treatment with TFF TAC FORT WORTH, Texas, Aug. 06, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today provided an update from the Company's ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant rejection. “The growing body of data from the TFF TAC Phase 2 study continues to suggest that TFF TAC has transformative potential to advance the field of immunosuppressive therapy to prevent lung transplant rejection,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals.

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

FORT WORTH, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company has engaged Outcome Capital as a strategic advisor for the purpose of evaluating potential corporate partnerships and licensing opportunities.

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

3 52-Week-Low Losers Ready to Become Big-Time Stock Winners

Bottom-picking stocks to buy is one of the most difficult strategies in trading and investing. It is a direct antithesis to the adage, “the trend is your friend, until it bends.

3 52-Week-Low Losers Ready to Become Big-Time Stock Winners

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

The Leidos team's Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company's Proprietary Thin Film Freezing Technology

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing

FORT WORTH, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that, in collaboration with Cleveland Clinic, the Company is advancing multiple multivalent universal influenza vaccines to protect against seasonal and pandemic viruses into preclinical testing. The decision to advance the vaccine candidates into preclinical testing was based upon the successful completion of formulation testing with stability data on the combination of hemagglutinin (HA) antigens with four different adjuvants. Based on these data, three HA antigen/adjuvant candidate vaccines have been selected for testing in a pre-clinical model at Cleveland Clinic Florida.

TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing

TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Patient Enrollment Has Accelerated with Now 10 Patients Enrolled in Phase 2 Trial 6 out of 6 Patients Who Completed the 12-Week Treatment Have Chosen to Remain on TFF TAC by Proceeding to the Safety Extension Phase; 1 patient has been treated for over a year and 3 additional patients have been treated for more than 6 months Variability in Systemic Exposure to Tacrolimus Was Reduced with TFF TAC Which Could Lower Risk of Acute Rejection and Systemic Toxicities FORT WORTH, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today provided an update from the Company's ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant rejection. “I am pleased to report that patient enrollment has accelerated due to positive physician enthusiasm based on emerging data, and we have now enrolled 10 patients in the TFF TAC Phase 2 study,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals.

TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Zacks Investment Research

TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates

TFF Pharmaceuticals, Inc. (TFFP) came out with a quarterly loss of $2.40 per share versus the Zacks Consensus Estimate of a loss of $2.20. This compares to loss of $4.75 per share a year ago.

TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates

See News Rankings